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1. The first limit to inference is the power of the study, which is
insufficient to rule out a genetic effect. Although the CE model
was reported as fitting the data best, the confidence intervals
for A (additive genetic effects) in the AE and ACE models are
very large. Both confidence intervals for A and C (shared
environment) contains 0 for the ACE model. A genetic effect
as large as 60% cannot be ruled out by this study. Accepting C
in place of A for discontinuous traits is logistically difficult
and would require a sample size of at least 20 000 twin pairs
given the prevalence of basal cell carcinomas of around 2%
(Neale et al, 1994).
2. The authors do not explore or comment on the significant
common environmental influence that has been observed,
which could merely be due to the age-dependence of BCCs.
The mean age of onset for sporadic BCC is around 65 years of
age, whilst familial tumours usually occur at younger age and
are often multiple (Kimonis et al, 1997). Failure to account for
age may mask the importance of a heritable component in the
data.
3. No account was taken of body sites. In genetically susceptible
families, it is well recognized that tumours are more often
found on the trunk than the face (Kimonis et al, 1997). By
combining all body sites in the analysis, it may have masked a
site-specific genetic effect.
4. Loss of heterozygosity studies have shown that 60% of BCCs
show loss of chromosome 9q, which harbour the patched
(PTC) gene (Gailani et al, 1992). Germline mutations in the
PTC gene are found in patients with naevoid BCC syndrome, a
family cancer syndrome characterized by multiple early onset
BCCs and developmental defects (Johnson et al, 1991). A
genetic basis for this disease is therefore likely and can only be
adequately discounted in much larger studies using designs
that take into account the known biological properties of the
disease.
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Hereditary factors in basal cell carcinoma of the skin:
a population-based cohort study in twins￿reply
Sir,
We thank Dr Bataille and her colleagues for their interest in our
paper on hereditary factors in basal cell carcinoma of the skin
(BCC), based on large population-based sample of adult twins
from Finland (Milan et al, 1998). They write that we concluded
that genetic factors are not necessary to explain the distribution of
BCC in twins, and raise a number of issues that they believe we
should have addressed.
It should first be pointed out that our conclusion was (as stated
in the last sentence of the abstract) that the results confirm the
major role of environmental factors, which was based on our
results from various genetic models shown in Table 4. In the
Introduction, we state that genetic disorders are known to be asso-
ciated with the development of BCC; in the Discussion, we
suggest that these disorders do not appear to be of major impor-
tance at the population level.
The decision to emphasise the best-fitting model, CE, with
shared (C) and unshared (E) environmental effects, derives from
the logic of model-fitting, which is to seek a model which accounts
for the observed data in the most parsimonious fashion, as advo-
cated by the standard text on twin analyses (Neale and Cardon,
1992). Such a model is more easily falsifiable in a subsequent
study than a more complex model, and we look forward to other
analyses of BCC from large, population-based twin or family data
sets. The more complex ACE-model did indeed contain the point
estimate of zero for both additive genetic effects (A) and shared
environmental effects (C), but the pure environmental model, E-
model, could be rejected. Nonetheless, in the ACE model, the
point estimate for the additive genetic component was 7.7%,
leaving over 90% of the inter-individual variability in the liability
to BCC to be attributed to environmental effects. The remaining
AE model, which Dr Bataille appears to be advocating, had a
poorer fit than the CE or ACE models.
Precisely because of the power issue (only four MZ and seven
DZ concordant pairs), we could not account for age effects in
genetic modelling. It certainly would be desirable to have more
twin pairs for such an analysis, but most twin study samples in the
world are considerably smaller than ours.
The mean age of diagnosis of the twins in the concordant pairs
was 64.1 years (range 38–82 years, both extremes being MZ male
twins, four out of 22 twins being diagnosed prior to age 60 years).
The twins from concordant pairs were not markedly younger than
were the other BCC patients on average. Failure to account for age
in genetic modelling thus appears to be an unlikely explanation for
not observing genetic effects.
Three-quarters (73%) of all BCCs registered with the Finnish
Cancer Registry between 1953 and 1995 were located in the head
and neck (unpublished data), compared with 68% of the twins
from the concordant pairs of the present study. One MZ pair (ages
at diagnosis 38 years and 43 years) and one DZ pair (60 and 61
years) were concordant for having a trunk location.
The identification of the role of the patched gene in the patho-
genesis of BCC is a very important observation, which we also
indicated (with three references) in our Discussion. However, the
basal cell naevus syndrome is a rare disease, and accounts for only
a very minor fraction of all BCCs in the population. The role of
germline mutations in the patched gene in sporadic BCC cases
should be assessed by the careful study of an unselected BCCpatient population and appropriate controls. A relatively small
number of patients should suffice to indicate whether such muta-
tions are relevant in sporadic BCC.
T Milan, J Kaprio, PK Verkasalo, CT Jansen, L Teppo and 
M Koskenvuo, Department of Public Health, University of Turku,
Lemminkäisenkatu 1, 20520 Turku, Finland
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The relation of gelatinase (MMP-2 and -9) expression
with distant site metastasis and tumour aggressiveness
in colorectal cancer
Sir,
We read with great interest the report by Parsons et al (1998) on
matrix metalloproteinase (MMP)-2 and -9 expression in gastro-
intestinal malignancy.
We agree with the authors on the significant role of MMP-2 and
-9 in the transformation of a tumour from the benign to the malig-
nant state by enabling the tumour cells to infiltrate blood vessels
and lymphatics allowing metastasis to a distant site. However,
since the distant site metastasis is an important aspect of the malig-
nancy, it brings a question about the specimens taken from the
patients having colorectal cancer, whether they do have metastasis
or not. The metastatic colorectal cancers should have been distin-
guished from the ones that have not metastasized yet. After then it
would be much more meaningful to make a comparison between
metastatic and non-metastatic groups according to their MMP-2
and -9 expressions in the primary sites.
Additionally, it would be also interesting to find out corre-
sponding results when one considers that some cases are likely to
have different organ preferences of metastasis. Moreover, as the
MMPs have been implicated in tumour progression (Liotta and
Stetler-Stevenson, 1990), with recent evidence suggesting that
MMPs are key regulators of the growth of tumours at both primary
and metastatic sites (Chambers and Matrisian, 1997), it would be
more meaningful to investigate the expressions of MMP-2 and -9
at metastatic sites as well as at primary sites.
On the other hand, all colorectal cancers were classified by the
Dukes’ staging system as well as other measures. Since only
Dukes’ stage A, B and C patients were defined in the results, it is
highly probable that the original Dukes’ staging system (Dukes,
1932) was used in the subdivision of colorectal cancers. Tumour
stage ‘D’ was not included in the original Dukes’ staging system
and also is not routinely included in Astler–Coller classification
(Astler and Coller, 1954) of carcinoma of the colon and rectum
which represents modification of classification proposed by
Dukes. However, it has become commonly used to represent
distant metastasis after addition into Astler–Coller classification
by Turnbull et al (1967).
Since stage ‘D’ is highly related to our topic and was not consid-
ered in the study we are not convinced of the conclusion that there
is no statistically significant correlation between gelatinase
expression and any of the recognized measures of tumour
aggressiveness.
Consequently, in the article neither there was a subdivision of
colorectal cancers as metastatic and non-metastatic nor tumour
stage ‘D’, which represents distant site metastasis has been
included in the staging of colorectal cancers. If the parts of the
investigation concerning the relation of gelatinase expression with
distant site metastasis and tumour aggressiveness were based upon
those above mentioned mainstays much more satisfactory results
of the study would be possible to be obtained.
I. H. Güllü, M. Kurdog ˘lu, Í. Akalın
Institute of Oncology, Hacettepe University, 
Ankara, Turkey
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